in this issue
Regions :: Western Europe :: Switzerland
Lonza and Teva discontinue biosimilars joint venture
7:47 AM MDT | July 25, 2013 | Deepti Ramesh
Lonza and Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel) today said that, following a strategic review, they have decided to discontinue the previously announced collaboration for the development, manufacturing, and marketing of biosimilars. Lonza and Teva had agreed, in 2009, to establish the biosimilars jv. Biosimilars are approved versions of innovator biopharmaceutical products, made after patent expiry of the innovator product. Doubts were raised about the future of the jv after Lonza CEO Richard Ridinger, in an interview with a Swiss business...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee